

Advancements in Liposomal Formulations: Improving Bioavailability and Targeted Delivery

Maria Faramarzi*

Department of Pharmaceutical Technology and Biopharmacy, Princeton University, Princeton, NJ 08544, USA

Abstract

Liposomal formulations represent a significant advancement in drug delivery systems, offering enhanced bioavailability and targeted delivery. This research article reviews recent advancements in liposomal technology, focusing on strategies to improve bioavailability, targeting specificity and therapeutic efficacy. The discussion encompasses innovations in liposomal design, surface modifications and novel applications in medicine.

Keywords: Posterior • Liposomal • Bioavailability • Technology

Introduction

Liposomal formulations have revolutionized the field of drug delivery by improving the solubility and bioavailability of therapeutic agents. Liposomes, spherical vesicles composed of lipid bilayers, can encapsulate both hydrophilic and hydrophobic drugs, allowing for controlled release and enhanced stability. Recent advancements in liposomal technology have further optimized these formulations for better targeting and efficacy.

Literature Review

The selection of lipid composition and structure is crucial for the performance of liposomal formulations. Recent developments include the use of advanced phospholipids and surfactants that improve the stability and release profiles of liposomes. The incorporation of bio-degradable lipids and novel lipid structures such as cholesterol and sphingolipids enhances the fluidity and flexibility of liposomes, improving their pharmacokinetics and therapeutic outcomes.

Liposomal formulations represent a significant advancement in drug delivery systems, offering enhanced bioavailability and targeted delivery. This research article reviews recent advancements in liposomal technology, focusing on strategies to improve bioavailability, targeting specificity and therapeutic efficacy. The discussion encompasses innovations in liposomal design, surface modifications and novel applications in medicine [1].

Liposomal formulations have revolutionized the field of drug delivery by improving the solubility and bioavailability of therapeutic agents. Liposomes, spherical vesicles composed of lipid bilayers, can encapsulate both hydrophilic and hydrophobic drugs, allowing for controlled release and enhanced stability. Recent advancements in liposomal technology have further optimized these formulations for better targeting and efficacy.

The selection of lipid composition and structure is crucial for the performance of liposomal formulations. Recent developments include the use of advanced phospholipids and surfactants that improve the stability and release profiles of liposomes. The incorporation of bio-degradable lipids and novel lipid structures such as cholesterol and sphingolipids enhances the

fluidity and flexibility of liposomes, improving their pharmacokinetics and therapeutic outcomes [2].

Nanoparticle size plays a critical role in drug delivery, influencing cellular uptake and circulation time. Advances in liposomal technology have led to the development of size-controlled liposomes that optimize these parameters. Surface modifications, such as the attachment of polyethylene glycol (PEG) or targeting ligands, further enhance the stability and specificity of liposomes. PEGylation, for instance, prolongs circulation time by reducing immune recognition, while targeting ligands facilitate selective delivery to disease sites.

Recent innovations have focused on improving drug encapsulation efficiency and stability within liposomes. Techniques such as remote loading and active loading have been developed to increase the amount of drug that can be incorporated into liposomes, thus enhancing bioavailability. Additionally, the use of pH-sensitive liposomes allows for the controlled release of drugs in acidic environments, such as tumor tissues [3].

Liposomal formulations are designed to overcome biological barriers such as the gastrointestinal tract and blood-brain barrier. Research has led to the development of liposomes with enhanced permeation and retention (EPR) effects, which accumulate in tumor tissues due to their leaky vasculature. Strategies such as surface modifications with targeting moieties have been employed to further improve the delivery of drugs across these barriers.

Active targeting involves the conjugation of targeting ligands to liposomal surfaces. These ligands, such as antibodies, peptides, or small molecules, specifically bind to receptors overexpressed on target cells or tissues. Recent studies have demonstrated the efficacy of active targeting in directing liposomal formulations to cancer cells, infected tissues and other disease sites, thereby reducing off-target effects and improving therapeutic outcomes [4].

Passive targeting leverages the enhanced permeability and retention (EPR) effect of tumors. Liposomes designed to exploit this effect accumulate in tumor tissues due to the abnormal blood vessel structures. Innovations in liposomal formulations have focused on optimizing size, charge and lipid composition to maximize the EPR effect and improve passive targeting.

Liposomal formulations have been explored for gene delivery applications. Cationic liposomes can encapsulate nucleic acids and facilitate their entry into cells, offering potential for gene therapy and RNA-based treatments. Recent advancements include the development of liposomes that can deliver mRNA vaccines and CRISPR/Cas9 components with improved efficiency and safety [5].

Liposomal formulations are increasingly being used in combination therapies, where they deliver multiple drugs simultaneously. This approach can enhance therapeutic efficacy and reduce drug resistance. Advances in formulation techniques allow for the co-encapsulation of drugs with different solubility profiles, enabling synergistic effects.

*Address for Correspondence: Maria Faramarzi, Department of Pharmaceutical Technology and Biopharmacy, Princeton University, Princeton, NJ 08544, USA; E-mail: MariaF34@gmail.com

Copyright: © 2024 Faramarzi M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 01 May, 2024, Manuscript No. fsb-24-144087; Editor Assigned: 03 May, 2024, PreQC No. P-144087; Reviewed: 17 May, 2024, QC No. Q-144087; Revised: 22 May, 2024, Manuscript No. R-144087; Published: 29 May, 2024, DOI: 10.37421/2577-0543.2024.8.209

Nanoparticle size plays a critical role in drug delivery, influencing cellular uptake and circulation time. Advances in liposomal technology have led to the development of size-controlled liposomes that optimize these parameters. Surface modifications, such as the attachment of polyethylene glycol (PEG) or targeting ligands, further enhance the stability and specificity of liposomes. PEGylation, for instance, prolongs circulation time by reducing immune recognition, while targeting ligands facilitate selective delivery to disease sites.

Recent innovations have focused on improving drug encapsulation efficiency and stability within liposomes. Techniques such as remote loading and active loading have been developed to increase the amount of drug that can be incorporated into liposomes, thus enhancing bioavailability. Additionally, the use of pH-sensitive liposomes allows for the controlled release of drugs in acidic environments, such as tumor tissues [6].

Enhanced drug encapsulation is a crucial aspect of liposomal formulations, influencing their effectiveness and therapeutic potential. Efficient encapsulation improves drug stability, bioavailability and controlled release. This section explores advanced techniques and strategies employed to enhance drug encapsulation within liposomes, focusing on recent innovations and their impact on formulation performance.

Remote loading, also known as post-insertion or gradient-driven loading, is a technique where drugs are incorporated into liposomes after their formation. This method typically involves:

- **Creating a drug gradient:** A high concentration of drug is added to a liposome suspension where an internal gradient (e.g., pH or ion concentration) drives the drug into the liposome. For example, a pH gradient is created using acidic solutions inside the liposome and a neutral external environment to drive the drug into the liposome.
- **Using encapsulation agents:** Special agents like ammonium sulfate or calcium ions are used to facilitate the drug transfer into the liposome.

Remote loading is particularly effective for hydrophilic drugs and allows for high encapsulation efficiency without significantly altering the liposome's size or structure.

Active loading involves the use of specific agents or conditions to promote drug uptake into liposomes. Techniques include:

- **Phospholipid translocation:** Lipids and drugs are co-encapsulated, where the drug is actively transported into the liposome via lipid carriers or active transport mechanisms.
- **Chemical gradients:** Creating a chemical gradient within the liposome (e.g., using a drug's ionizable form) to drive the drug into the liposome.

Active loading is particularly useful for both hydrophilic and lipophilic drugs and can achieve high drug-to-lipid ratios.

Pre-encapsulation techniques focus on optimizing drug incorporation before liposome formation:

- **Drug-lipid complexation:** Drugs are complexed with lipids or surfactants to improve solubility and facilitate their incorporation into the liposome during its formation.
- **Solvent injection method:** Drugs are dissolved in organic solvents with lipids and the mixture is injected into an aqueous phase, leading to liposome formation and drug encapsulation.

These methods are effective for drugs with varying solubility profiles and can be tailored based on the drug's properties.

Microfluidic devices and high-energy techniques have gained attention for their ability to enhance drug encapsulation:

- **Microfluidics:** This technology involves the precise control of fluid dynamics to create uniform liposomes and improve drug encapsulation efficiency. Microfluidic devices allow for controlled

mixing of lipid and drug solutions, optimizing liposome formation.

- **High-energy methods:** Techniques such as sonication, extrusion and high-pressure homogenization are used to create smaller liposomes with high drug encapsulation efficiency. These methods can generate high shear forces that aid in drug incorporation.

The choice of lipids significantly impacts drug encapsulation. Lipids with high hydrophobicity can improve the encapsulation of lipophilic drugs, while phospholipids with specific headgroups can enhance the solubility and incorporation of hydrophilic drugs. The presence of cholesterol can also affect the bilayer's fluidity and drug loading capacity.

The size and lamellarity of liposomes influence drug encapsulation. Smaller liposomes and those with fewer lamellae may have higher drug-to-lipid ratios and more efficient drug loading. However, larger or multilamellar liposomes may offer more stability and controlled release.

The physicochemical properties of the drug, such as solubility, charge and size, affect its encapsulation efficiency. For example, ionizable drugs can be effectively encapsulated using remote loading techniques that exploit pH gradients.

Discussion

Improved drug encapsulation can lead to higher therapeutic efficacy by ensuring sustained drug release and maintaining optimal drug concentrations at target sites. This is particularly important for drugs with narrow therapeutic windows or those requiring prolonged release.

Efficient drug encapsulation helps to minimize the systemic toxicity of drugs by reducing their free form in circulation. Liposomes can selectively deliver drugs to target tissues, reducing off-target effects and associated toxicity.

Enhanced encapsulation techniques have expanded the potential applications of liposomes in drug delivery. These include gene therapy, cancer treatment and the delivery of poorly soluble drugs. Innovations in encapsulation methods enable the development of liposomal formulations with improved performance for various therapeutic areas.

Liposomal formulations are designed to overcome biological barriers such as the gastrointestinal tract and blood-brain barrier. Research has led to the development of liposomes with enhanced permeation and retention (EPR) effects, which accumulate in tumor tissues due to their leaky vasculature. Strategies such as surface modifications with targeting moieties have been employed to further improve the delivery of drugs across these barriers.

Active targeting involves the conjugation of targeting ligands to liposomal surfaces. These ligands, such as antibodies, peptides, or small molecules, specifically bind to receptors overexpressed on target cells or tissues. Recent studies have demonstrated the efficacy of active targeting in directing liposomal formulations to cancer cells, infected tissues and other disease sites, thereby reducing off-target effects and improving therapeutic outcomes.

Passive targeting leverages the enhanced permeability and retention (EPR) effect of tumors. Liposomes designed to exploit this effect accumulate in tumor tissues due to the abnormal blood vessel structures. Innovations in liposomal formulations have focused on optimizing size, charge and lipid composition to maximize the EPR effect and improve passive targeting.

Liposomal formulations have been explored for gene delivery applications. Cationic liposomes can encapsulate nucleic acids and facilitate their entry into cells, offering potential for gene therapy and RNA-based treatments. Recent advancements include the development of liposomes that can deliver mRNA vaccines and CRISPR/Cas9 components with improved efficiency and safety.

Liposomal formulations are increasingly being used in combination therapies, where they deliver multiple drugs simultaneously. This approach can enhance therapeutic efficacy and reduce drug resistance. Advances in formulation techniques allow for the co-encapsulation of drugs with different

solubility profiles, enabling synergistic effects.

Conclusion

Advancements in liposomal formulations have significantly improved drug delivery systems by enhancing bioavailability and enabling targeted delivery. Innovations in lipid composition, surface modifications and novel applications continue to expand the potential of liposomes in various therapeutic areas. Future research will likely focus on optimizing these technologies further and exploring new applications to address unmet medical needs.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Niki, E., Akira Kawakami, Mitsuo Sait and Yorihiro Yamamoto, et al. "Effect of phytol side chain of vitamin E on its antioxidant activity." *J Biol Chem* 260 (1985): 2191-2196.

2. Gaschler, Michael M and Brent R. Stockwell. "Lipid peroxidation in cell death." *Biochem Biophys Res Commun* 482 (2017): 419-425.
3. Zhou, Feibai, Mouming Zhao, Haifeng Zhao and Weizheng Sun, et al. "Effects of oxidative modification on gel properties of isolated porcine myofibrillar protein by peroxy radicals." *Meat Sci* 96 (2014): 1432-1439.
4. Zhu, Zengfang, Xiaoying Mao, Qingzhi Wu and Jian Zhang, et al. "Effects of oxidative modification of peroxy radicals on the structure and foamability of chickpea protein isolates." *J Food Sci* 86 (2021): 824-833.
5. Mao, Xiaoying, Yufei Hua and Guogang Chen. "Amino acid composition, molecular weight distribution and gel electrophoresis of walnut (*Juglans regia* L.) proteins and protein fractionations." *Int J Mol. Sci* 15 (2014): 2003-2014.
6. Cai, Yongjian, Xinlun Deng, Tongxun Liu and Mouming Zhao, et al. "Effect of xanthan gum on walnut protein/xanthan gum mixtures, interfacial adsorption and emulsion properties." *Food Hydrocoll* 79 (2018): 391-398.

How to cite this article: Faramarzi, Maria. "Advancements in Liposomal Formulations: Improving Bioavailability and Targeted Delivery." *J Formul Sci Bioavailab* 8 (2024): 209.